



Public Health
England



Treatment of MERS-CoV: Information for Clinicians

Clinical decision-making support for treatment of MERS-CoV patients

v2.0 14 July 2014

About Public Health England

Public Health England exists to protect and improve the nation's health and wellbeing, and reduce health inequalities. It does this through advocacy, partnerships, world-class science, knowledge and intelligence, and the delivery of specialist public health services. PHE is an operationally autonomous executive agency of the Department of Health.

This document was created by PHE and the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) as a resource for use by UK healthcare professionals, and is made available internationally through ISARIC. It is a living document that will be updated regularly.

Public Health England
Wellington House
133-155 Waterloo Road
London SE1 8UG
Tel: 020 7654 8000
www.gov.uk/phe
Twitter: @PHE_uk
Facebook: www.facebook.com/PublicHealthEngland

For queries relating to this document, please contact: meera.chand@phe.gov.uk

© Crown copyright 2014

You may re-use this information (excluding logos) free of charge in any format or medium, under the terms of the Open Government Licence v2.0. To view this licence, visit [OGIL](http://www.ogil.io) or email psi@nationalarchives.gsi.gov.uk. Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.

Published July 2014

PHE publications gateway number: 2014215



Contents

About Public Health England	2
1 Document scope	4
2 Literature	4
3 SARS-CoV approximation of MERS-CoV	5
4 Evidence base	5
5 Management of case	6
5.1 Infection control	6
5.2 Routine investigations	6
5.3 Approach to treatment	6
5.4 Specific therapies	6
5.5 Combination therapy	7
6 Feedback	14
7 Useful links	14
8 Document authors	14
9 Consultation	15
10 Bibliography: articles of interest	16

1 Document scope

This document is intended to provide an overview of available evidence and experience on investigational therapeutics for clinicians treating confirmed cases of MERS-CoV.

It was produced by PHE and the International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC) for the use of UK clinicians.

It is informed by literature concerning SARS, pandemic 2009 H1N1 influenza and MERS, as well discussions with international experts convened through ISARIC.

2 Literature

This document takes much of the SARS information from the following systematic review of SARS treatment: Stockman LJ, Bellamy R, Garner P (2006) SARS: Systematic review of treatment effects. PLoS Med 3(9): e343. DOI: 10.1371/journal.pmed.0030343.

Two recent reviews are also available: Cheng VCC et al, Clinical management and infection control of SARS: lessons learned, published in *Antiviral Research* (2013;100:407-419) and Momattin H et al, Therapeutic Options for MERS-CoV – possible lessons from a systematic review of SARS-CoV therapy, published in the *International Journal of Infectious Diseases* (2013;17:e792–e798). Colleagues with experience of managing MERS-CoV patients in affected countries have also reviewed treatment options for MERS-CoV (see bibliography and Momattin H et al, 2013)

A list of references used in this analysis is given at the end of this document. A regular literature review has been performed to ensure that evolving evidence is captured. Some information contained herein is unpublished *in vitro* and animal model work on MERS-CoV from several international groups to whom we are indebted. Experts consulted are listed at the end.

3 SARS-CoV approximation of MERS-CoV

Although we draw inferences from SARS in this document, there are important differences between SARS and MERS coronaviruses (CoVs), and some areas in which MERS-CoV data is not yet sufficient to enable comparison. MERS- and SARS-CoV infections demonstrate different in vitro virological and immunological characteristics but the clinical relevance of these are unknown.

The limited evidence available on viral dynamics and clinical course suggest that MERS-CoV patients have shorter time from illness onset to clinical presentation and requirement for ventilatory support (median seven days; range 3-11) than SARS-CoV patients, as well as associated higher respiratory tract viral loads during the first week of the illness. Some therapeutic options that showed apparent clinical effects in observational human trials of SARS-CoV patients have not demonstrated in vitro inhibition of MERS-CoV.

4 Evidence base

Therapies that are plausible and supported by reasonable in vitro, animal and/or clinical data from MERS-CoV or other respiratory virus infections are shown in Table 1. A large number of other compounds have been evaluated for in vitro inhibition against MERS-CoV and some have demonstrated an inhibitory effect at concentrations that might be achieved in patients.

However, without animal studies or well-documented experience of clinical use in comparable contexts, these are not currently ready for clinical use in MERS-CoV patients.

5 Management of case

5.1 Infection control

Effective infection control is essential to protect staff and patients. Instigate measures as described in the PHE guidelines

(www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317136232722).

5.2 Routine investigations

PHE will advise clinicians on samples for clinical and infection control purposes. We recommend that routine specimens include upper and lower respiratory tract, blood, stool and urine.

For organisations considering studies, ISARIC has developed a generic biological sampling protocol (www.prognosis.org/isaric) and case report forms

(www.prognosis.org/isaric/crf.php).

5.3 Approach to treatment

The most important recommendation remains that high-quality supportive care is the keystone of management, as expressed in the Surviving Sepsis Campaign guidelines for the care of the critically ill and the WHO Interim Guidance on MERS:

www.who.int/csr/disease/coronavirus_infections/InterimGuidance_ClinicalManagement_NovelCoronavirus_11Feb13u.pdf?ua=1.

Any additional benefit of investigational pharmacological agents is uncertain, because of lack of evidence, rather than lack of plausibility. Treatment with specific therapeutic agents should ideally occur in the context of formal observational studies or controlled intervention trials (see <https://isaric.tghn.org/protocols/sari-bsp/> for open access protocols).

In the UK, two centres have experience of managing severely ill patients with MERS. Consultation with staff in these centres may be helpful. PHE will facilitate communications if required.

5.4 Specific therapies

Based on the evidence presented in Table 1, convalescent plasma, interferon and lopinavir may be considered for specific treatment of MERS-CoV patients. Interferon and lopinavir are likely to be the most accessible initial treatments. PHE will advise on

the availability of convalescent plasma once a case is identified. Specific MERS-CoV monoclonal and polyclonal antibodies are in development at the time of writing. UK physicians should contact PHE (Professor Maria Zambon's office, 020 8327 6810) for information about the current availability of monoclonal or polyclonal antibodies.

Other agents described in Table 1 have demonstrated antiviral effects in vitro, but without documented in vivo efficacy or sufficient clinical data. Some are associated with concerns about safety in clinical practice. Many require safety studies, animal studies, or both before clinical trials can be initiated. Expert consensus is to avoid those agents classified as "red", ie corticosteroids for specific treatment of MERS, and ribavirin. In some patients corticosteroids may be considered for other indications according to local policy, for example exacerbations of asthma/COPD, suspected or documented adrenal insufficiency or refractory septic shock (in line with Surviving Sepsis International Guidelines and WHO Interim Guidance on MERS).

The effect of steroids on viral clearance in MERS is unknown, although systemic corticosteroid administration delayed clearance of SARS-CoV and has been associated with prolonged replication of other respiratory viruses. Consequently, serial sampling with PCR testing should be performed in any patients who do receive steroids for any indication.

5.5 Combination therapy

Therapeutic agents were used in multiple combinations for treatment of SARS patients but there are inadequate data to disentangle the effects of individual agents from the possible benefits of any combinations. Limited data from in vitro and animal studies of MERS-CoV infection suggests a possible synergistic effect from combining interferon (IFN) and ribavirin. However, the concentrations of ribavirin used are much higher than those used to treat hepatitis C virus infection. Available data is inadequate to decide whether any benefit conferred by an interferon/ribavirin synergy outweighs the risk of ribavirin toxicity. Therefore, this combination is not recommended unless it is used in an appropriately planned clinical trial.

Table 1. Evidence base for specific therapies for MERS-CoV infection

Therapy	Studies conducted	Data: SARS and other respiratory viruses	Data: MERS	Safety profile	UK feasibility
GREEN: Benefit is likely to exceed risk					
Convalescent plasma (or high neutralising antibody titre products)	SIV; SA; SC; MIV	RCT not performed in SARS. One RCT supports use of hyperimmune globulin in severe A(H1N1)pdm09 influenza. Observational data suggests efficacy in SARS, A(H1N1)pdm09 and other influenza virus infections. A pooled meta-analysis including SARS-CoV and influenza studies showed a significantly lower risk of mortality in those treated with convalescent plasma or serum.	<i>In vitro</i> neutralizing effect. No MERS-CoV animal or human studies have been published, but studies are in progress in 2014.	Good safety profile in UK, risks as for other blood products.	Availability depends on UK epidemiological situation. Please contact PHE for an update on availability.
Interferons	SIV; SA; SC; MIV; MA	Type I (α , β), type II (γ), and type III (λ) interferons show activity against SARS in extensive <i>in vitro</i> and limited animal and observational clinical studies.	<i>In vitro</i> , MERS-CoV appears to be more sensitive to Type I IFNs than SARS-CoV, especially IFN- β . Animal studies with Poly IC topical IFN inducer suggest efficacy. IFN- α in combination with ribavirin shows some efficacy in non-human primates, but this animal	Well established agent. Clinicians experienced in managing side-effects should be consulted eg those treating hepatitis C virus (HCV) infection and multiple sclerosis. Consideration should be given to shorter-acting preparations compared to peg-IFNs.	Injectable interferon β is currently first choice and is routinely available. Inhaled interferon β is currently in Phase 2 trials.

			model does not accurately reflect severe MERS illness seen in humans.		
Lopinavir	SIV; SA; SC; MIV	Limited data that HIV protease inhibitors have in vitro anti-SARS-CoV effect. Observational studies suggest clinical benefits in SARS patients treated with lopinavir/ritonavir, including a reduction in mortality reported in one study.	Lopinavir inhibitory for MERS-CoV in vitro at concentrations observed in blood during clinical use. (Note other HIV PIs tested, atazanavir and ritonavir, were inactive).	Well established agent with favourable toxicity profile. Gastrointestinal side-effects are common but self-limiting.	Routinely available (as lopinavir/ritonavir combination preparation)
Monoclonal and polyclonal neutralising antibodies	SIV; SA; MIV	Strong in vitro neutralising effect against the SARS-CoV spike protein.	Novel monoclonal antibodies to MERS-CoV spike protein have strong neutralising effect.	Human safety studies will be conducted before individual products made available. In those products which have satisfied UK regulatory safety requirements, benefit is likely to exceed risk.	Contact PHE for an update on availability. Use should be within a trial, or if not possible, through a compassionate use arrangement.

YELLOW: Data is inadequate for assessment					
<i>Interferon + ribavirin (combination therapy)</i>	SIV; SA; SC; MIV; MA; MC	Synergistic effect in vitro and in animal model when ribavirin combined with IFN- β . Effect of combination could not be distinguished from other concurrent treatments in SARS patients. Where outcomes could be determined, adverse effects were reported.	IFN- α 2b and ribavirin combined in vitro had anti-MERS-CoV effect at lower concentration than when used separately. Combination IFN- α 2b and ribavirin in MERS rhesus macaque model led to clinical, radiographic and virological improvements. IFN/ribavirin combination therapy given late in illness to 5 MERS patients did not prevent death. Recent case reports of apparent benefit when used for early therapy or post-contact prophylaxis.	Adverse effects of ribavirin were frequent in SARS clinical studies (see ribavirin, below). In combination studies, the experimental ribavirin concentrations were higher than those observed clinically during treatment of hepatitis C.	Routinely available. Data is inadequate to decide whether any benefit conferred by possible interferon/ribavirin synergy outweighs the risk of ribavirin toxicity.
<i>Nitazoxanide</i>	MIV	No SARS data. Two RCTs show benefit in childhood respiratory infections and uncomplicated influenza in adults, respectively. Inhibitory for one non-human CoV in vitro.	No activity in vitro against MERS-CoV. No animal model data available.	Well established agent with defined safety profile.	Routinely available.

Treatment of MERS-CoV: Information for Clinicians
 Clinical decision-making support for treatment of MERS-CoV patients

<i>Mycophenolic acid</i>	SIV; SA; MIV	No effect on SARS-CoV in vitro or in murine model.	Inhibits MERS-CoV in vitro, with a concentration achievable by standard clinical oral dosing. Synergy in vitro with IFN- β 1b. MERS-CoV animal studies are in progress. No MERS clinical studies.	Effect of transient immunosuppressive activity in this context is uncertain. Established treatment with multiple well characterised side-effects.	Routinely available.
<i>Chloroquine</i>	SIV;MIV	Inhibitory in vitro for multiple viruses including influenza. No consistent activity in animal models of influenza and negative results in one influenza RCT of seasonal prophylaxis.	Inhibits MERS-CoV in vitro, with a concentration achievable by standard clinical oral dosing.	Well established agent with defined safety profile.	Routinely available

RED: Risk is likely to exceed benefit					
<i>Corticosteroids (as specific therapy for MERS-CoV infection)</i>	SA; SC;	<p>A SARS-CoV animal study suggests early anti-inflammatory effects but found ongoing administration may enhance viral replication in the lung. SARS clinical studies found no mortality benefit. Some observational studies found clinical improvements after treatment, but one RCT found increased viral load associated with corticosteroid treatment</p> <p>Use of systemic corticosteroids in patients with severe influenza A(H1N1)pdm09 was also associated with increased risks of prolonged lower respiratory tract viral replication, nosocomial infections, ventilator-associated pneumonia, and higher mortality in observational studies.</p>	No studies available. Given to many MERS patients under uncontrolled circumstances.	SARS studies found no mortality benefit and evidence for adverse effects of systemic steroids, with both acute and long-term harms, including delayed viral clearing reported, and increased opportunistic infections. Osteonecrosis was observed following pulsed methylprednisolone.	
<i>Ribavirin – monotherapy</i>	SIV; SA; SC; MIV; MC	Four of six in vitro SARS studies found an antiviral effect. No virological effects were found on SARS in animal models as monotherapy. In SARS clinical studies, the effect of ribavirin could not be distinguished from	MERS-CoV is inhibited by ribavirin at very high concentrations in vitro. These exceed concentrations achievable during clinical use, except possibly for	Studies of ribavirin in large numbers of SARS patients found frequent adverse effects including haemolysis, metabolic disturbances, and liver function test	

		the effects of other therapies.	high IV dosages. No animal monotherapy studies have been conducted. Combination therapy including ribavirin was given to five MERS patients late in the illness and did not prevent death.	derangement.	
<i>UK intravenous human normal immunoglobulin (IVIG)</i>	SC; MIV	Five SARS studies conducted; all inconclusive as used IVIG as part of combination therapy. In one uncontrolled study in Hong Kong, 12 patients who had deteriorated despite other therapies were given IVIG as an additional therapy, with evidence of subsequent improvement.	PHE evaluation shows that UK IVIG has no evidence of MERS-CoV neutralising activity. IVIG from endemic countries requires separate evaluation.	Commercial intravenous immunoglobulin products have been associated with rare acute renal failure and thromboembolic events.	

* SARS in vitro (SIV); SARS animal (SA); SARS clinical (SC); MERS-CoV in vitro (MIV); MERS animal (MA); MERS clinical (MC)

6 Feedback

As this is a document intended for continual update, we are particularly interested in the views of those who may be using it on the frontline of service. Please send thoughts or suggestions for improvement, or any other comments, to colin.brown@phe.gov.uk and meera.chand@phe.gov.uk.

7 Useful links

PHE – www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/NovelCoronavirus2012/

ISARIC – <http://www.isaric.org>

WHO –

www.who.int/csr/disease/coronavirus_infections/update_20130517/en/index.html

ECDC – www.ecdc.europa.eu/en/healthtopics/coronavirus-infections/pages/index.aspx

CDC – www.cdc.gov/features/novelcoronavirus/

8 Document authors

Dr Colin Brown^{1,2}

Dr Gail Carson³

Dr Meera Chand^{1,5}

Dr Jake Dunning^{3,4}

Professor Maria Zambon¹

¹ Microbiology Services, Public Health England, UK

² Department of Medical Microbiology, Royal Free Hospital, UK

³ International Severe Acute Respiratory & Emerging Infection Consortium (ISARIC), UK

⁴ Centre for Respiratory Infection, Imperial College London, UK

⁵ Guy's & St Thomas' Hospitals NHS Foundation Trust, UK

9 Consultation

The following coronavirus experts and clinicians and scientists with experience of SARS, MERS-CoV, and other respiratory viruses were involved in PHE or ISARIC teleconferences or commented on drafts of this document. We are most grateful to them all for their valued input.

Contributors involved in literature review, documentation, and draft development:

Ken Baillie, University of Edinburgh, UK

Nick Barrett, Guy's & St Thomas' Hospitals NHS Foundation Trust

Katrina Barlow, Public Health England, UK

Nichola Goddard, Public Health England, UK

Eli Harris, ISARIC, UK

Kajsa-Stina Longuere, ISARIC, UK

Nick Phin, Public Health England, UK

John Watson, Public Health England, UK

International experts invited to comment on basis of experience of SARS/H5N1/critical care, or to contribute unpublished data:

Abdullah Brooks, Johns Hopkins University, US

Jeremy Farrar, Oxford University Clinical Research Unit, Vietnam

Heinz Feldman, National Institute of Allergy and Infectious Diseases, National Institutes of Health, US

Ron Fouchier, Erasmus Medical Center, The Netherlands

Rob Fowler, University of Toronto, Canada

Bart Haagmans, Erasmus Medical Center, The Netherlands

Frederick Hayden, University of Virginia School of Medicine, US

David Hui, Chinese University of Hong Kong, China

Eric Snijder, University Medical Center Leiden, The Netherlands

WHO staff:

Nikki Shindo, World Health Organization, Switzerland

Clinicians, virologists, health professionals, and public health experts involved in managing MERS-CoV patients:

Many thanks to all who participated in the PHE and ISARIC/WHO teleconferences for their valuable input.

10 Bibliography: articles of interest

Antibiotics

1. Sung JJ, Wu A, Joynt GM, et al. Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. *Thorax* 2004;59(5):414-20. Download the PDF from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1746995/pdf/v059p00414.pdf>

Chloroquine

1. Vigerust DJ, McCullers JA. Chloroquine is effective against influenza A virus in vitro but not in vivo. *Influenza Other Respi Viruses*. 2007 Sep-Nov;1(5-6):189-92. Download the PDF from: <http://onlinelibrary.wiley.com/doi/10.1111/j.1750-2659.2007.00027.x/pdf>

2. Paton NI, Lee L, Xu Y, et al. Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial. *Lancet Infect Dis*. 2011 Sep;11(9):677-83. Download the PDF from: [http://www.thelancet.com/journals/laninf/article/PIIS1473-3099\(11\)70065-2/fulltext](http://www.thelancet.com/journals/laninf/article/PIIS1473-3099(11)70065-2/fulltext)

3. Yan Y, Zou Z, Sun Y, Li X, Xu K, We Yi, Jin N, Jiang C. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. *Cell Res*. Feb 2013; 23(2):300–302. Download the PDF from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3567830/pdf/cr2012165a.pdf>

4. Paton NI, Lee L, Xu Y, Ooi EE, Cheung YB, Archuleta S, Wong G, Wilder-Smith A . Chloroquine for influenza prevention: a randomised, double-blind, placebo controlled trial. *Lancet Infect Dis*. 2011;11(9):677-83. Download the PDF from: <http://download.thelancet.com/pdfs/journals/laninf/PIIS1473309911700652.pdf?id=eaaoHFZmdX5W2fRawjgBu>

5. Ooi EE, Chew JS, Loh JP, Chua RC. In vitro inhibition of human influenza A virus replication by chloroquine. *Virology*. 2006;3:39. Download the PDF from: <http://www.virologyj.com/content/3/39>

6. Vigerust DJ, McCullers JA. Effectiveness of chloroquine against influenza. *Influenza and Other Respiratory Viruses* 2008;1(5-6):189–192. Available at: <http://www.medscape.com/viewarticle/570833>

Convalescent plasma

1. Cheng Y, Wong R, Soo YO, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. *European J Clin Micro* 2005;24(1):44-6. Download the PDF from: http://download.springer.com/static/pdf/506/art%253A10.1007%252Fs10096-004-1271-9.pdf?auth66=1362220920_4b68188c5ad3755a49b8647b565fa1d9&ext=.pdf

2. Yeh KM, Chiueh TS, Siu LK, et al. Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital. *J Antimicrob Chemother* 2005;56(5):919-22. Download the PDF from: <http://jac.oxfordjournals.org/content/56/5/919.full.pdf+html>

3. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. *PLoS Med* 2006;3(9):e343. Download the PDF from:
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1564166/pdf/pmed.0030343.pdf>
4. Wong SSY, Yuen KY. The management of coronavirus infections with particular reference to SARS. *J Antimicrob Chemoth* 2008;62(3):437-41. Download the PDF from:
<http://jac.oxfordjournals.org/content/62/3/437.full.pdf+html>
5. Hung IF, To KK, Lee CK, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. *Clin Infect Dis*. 2011 Feb 15;52(4):447-56.. Download the PDF from: <http://cid.oxfordjournals.org/content/52/4/447.long>
6. Zhong X, Yang H, Guo Z, et al. B-Cell Responses in Patients Who Have Recovered from Severe Acute Respiratory Syndrome Target a Dominant Site in the S2 Domain of the Surface Spike Glycoprotein. *J Virol* 2005;79(6):3401-3408. Download the PDF from: <http://jvi.asm.org/content/79/6/3401.full>
7. Hung IF, To KK, Lee CK, et al. Hyperimmune Intravenous Immunoglobulin Treatment: A Multicentre Double-Blind Randomized Controlled Trial for Patients with Severe A(H1N1)pdm09 Infection. *Chest* 2013;144(2):464-473. Download the PDF from:
<http://journal.publications.chestnet.org/article.aspx?articleid=1656407>
8. Chan KH, Chan JF, Tse H, et al. Cross-reactive antibodies in convalescent SARS patients' sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests. *J Infect* 2013;67(2):130-140. Download the PDF from:
<http://www.sciencedirect.com/science/article/pii/S0163445313000716>
9. ter Meulen J, Bakker AB, van den Brink EN, et al. Human monoclonal antibody as prophylaxis for SARS coronavirus infection in ferrets. *Lancet* 2004;363(9427):2139-41. Download the PDF from:
[http://www.thelancet.com/journals/lancet/article/PIIS0140-6736\(04\)16506-9/fulltext](http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(04)16506-9/fulltext)
10. Roberts A, Thomas WD, Guarner J, et al. Therapy with a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody reduces disease severity and viral burden in golden Syrian hamsters. *J Infect Dis* 2006;193(5):685-92. Download the PDF from:
<http://jid.oxfordjournals.org/content/193/5/685.long>
11. Mair-Jenkins J, Saavedra-Campos M, Baillie K et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral aetiology: a systematic review and exploratory meta-analysis. *J Infect Dis*; epub July 16 2014doi:10.1093/infdis/jiu396. Download the PDF from
<http://jid.oxfordjournals.org/content/early/2014/07/16/infdis.jiu396.full.pdf+html>

Corticosteroids

1. Loutfy MR, Blatt LM, Siminovitch KA, et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. *JAMA* 2003;290(24):3222-8. Download the PDF from:
<http://jama.jamanetwork.com/data/Journals/JAMA/4909/JPC30087.pdf>
2. Lee N, Allen Chan KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. *J Clin Viro* 2004;31(4):304-9. Download the PDF from: <http://www.sciencedirect.com/science/article/pii/S1386653204001957>

3. Sung JJ, Wu A, Joynt GM, et al. Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. *Thorax* 2004;59(5):414-20. Download the PDF from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1746995/pdf/v059p00414.pdf>
4. Levy MM, Baylor MS, Bernard GR, et al. Clinical issues and research in respiratory failure from severe acute respiratory syndrome. *Am J Resp Crit Care* 2005;171(5):518-26. Download the PDF from: <http://ajrcm.atsjournals.org/content/171/5/518.full.pdf+html>
5. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. *PLoS Med* 2006;3(9):e343. Download the PDF from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1564166/pdf/pmed.0030343.pdf>
6. Wong SSY, Yuen KY. The management of coronavirus infections with particular reference to SARS. *J Antimicrob Chemoth* 2008;62(3):437-41. Download the PDF from: <http://jac.oxfordjournals.org/content/62/3/437.full.pdf+html>
7. Zhang X, Alekseev K, Jung K, Vlasova A, Hadya N, Saif LJ. Cytokine responses in porcine respiratory coronavirus-infected pigs treated with corticosteroids as a model for severe acute respiratory syndrome. *J Viro* 2008;82(9):4420-8. <http://europemc.org/articles/PMC2293053?pdf=render>
8. Sessler CN, Gay PC. Are corticosteroids useful in late-stage acute respiratory distress syndrome? *Respir Care* 2010;55(1):43-55. Download the PDF from: <http://rc.rcjournal.com/content/55/1/43.short>
9. Kim SH, Hong SB, Yun SC, et al. Corticosteroid treatment in critically ill patients with pandemic influenza A/H1N1 2009 infection: analytic strategy using propensity scores. *Am J Respir Crit Care Med* 2011;183(9):1207-14. Download the PDF from: <http://www.atsjournals.org/doi/pdf/10.1164/rccm.201101-0110OC>
10. Griffith JF, Antonio GE, Kumta SM, et al. Osteonecrosis of hip and knee in patients with severe acute respiratory syndrome treated with steroids. *Radiology* 2005;235(1):168-75. Download the PDF from: <http://radiology.rsna.org/content/235/1/168.long>
11. Tang BM, Craig JC, Eslick GD, et al. Use of corticosteroids in acute lung injury and acute respiratory distress syndrome: a systematic review and meta-analysis. *Crit Care Med* 2009;37(5):1594-603. Download the PDF from: <http://criticalcaremedicine.pbworks.com/f/tang+2010+crit+care+med.pdf>
12. Khilnani GC, Hadda V. Corticosteroids and ARDS: A review of treatment and prevention evidence. *Lung India* 2011;28(2):114–119. Download the PDF from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3109833/?report=reader>

Cyclosporin

1. de Wilde AH, Zevenhoven-Dobbe JC, van der Meer Y, et al. Cyclosporin A inhibits the replication of diverse coronaviruses. *J Gen Virol* 2011;92(Pt 11):2542-8. Download the PDF from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3352363/>
2. Pfefferle S, Schopf J, Kogl M, et al. The SARS-coronavirus-host interactome: identification of cyclophilins as target for pan-coronavirus inhibitors. *PLoS Path* 2011;7(10):e1002331. Download the PDF from: <http://www.plospathogens.org/article/info%3Adoi%2F10.1371%2Fjournal.ppat.1002331>

3. de Wilde AH, Ray VS, Oudshoorn D, Bestebroer TM, van Nieuwkoop S, Limpens RW, Posthuma CC, van der Meer Y, Bárcena M, Haagmans BL, Snijder EJ, van den Hoogen BG. Human coronavirus-EMC replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon-alpha treatment. *J Gen Virol* 2013;94(12):2679-2690. Download the PDF from: <http://vir.sgmjournals.org/content/early/2013/04/24/vir.0.052910-0.long>

4. De Wilde AH, Raj VS, Oudshoorn D, et al. MERS-coronavirus replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon- α treatment. *J Gen Virol*. 2013 August; 94(Pt 8): 1749–1760. Download the PDF from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749523/pdf/1749.pdf>

Cytokines and chemokines

1. Glass WG, Subbarao K, Murphy B, Murphy PM. Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice. *J Immunol* 2004;173(6):4030-39. Download the PDF from: <http://www.jimmunol.org/content/173/6/4030.full.pdf+html>

2. Wong CK, Lam CW, Wu AK, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. *Clinical Exp Immunol* 2004;136(1):95-103. Download the PDF from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1808997/pdf/cei0136-0095.pdf>

3. Lau SKP, Lau CCY, Chan K, et al. Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implications for pathogenesis and treatment. *J Gen Virol* 2013;94(12):2679-2690. Download the PDF from: http://vir.sgmjournals.org/content/94/Pt_12/2679.full.pdf+html

4. Shirato K, Kawase M, Matsuyama S. Middle East Respiratory Syndrome Coronavirus Infection Mediated by the Transmembrane Serine Protease TMPRSS2. *J Virol* 2013; 87 (23):12552-61. Download the PDF from: <http://jvi.asm.org/content/87/23/12552.full.pdf+html>

General

1. Bosma KJ, Taneja R, Lewis JF. Pharmacotherapy for prevention and treatment of acute respiratory distress syndrome: Current and experimental approaches. *Drugs* 2010;70(10):1255-82. Abstract only: <http://www.ncbi.nlm.nih.gov/pubmed/20568833>

2. DuVernoy T, Briese T, et al. Panel discussion - Viral respiratory pathogens. *Influenza Other Respi Viruses* 2010;4:21-22. Download the PDF from: <http://onlinelibrary.wiley.com/doi/10.1111/j.1750-2659.2010.00136.x/pdf>

3. Barnard DL, Kumaki Y. Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy. *Future Virol* 2011;6(5):615-31. Download the PDF from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3136164/pdf/nihms304163.pdf>

4. Josset L, Menachery VD, Gralinski LE, et al. Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus. *mBio* 2013;4(3):e00165-13. Download the PDF from: <http://mbio.asm.org/content/4/3/e00165-13>

5. Dellinger RP, Levy MM, Rhodes A, et al; Surviving Sepsis Campaign Guidelines Committee including the Pediatric Subgroup. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2008. *Crit Care Med* 2008; 36:296–327. Download the PDF from:
http://www.survivingsepsis.org/About_the_Campaign/Documents/Final%2008%20SSC%20Guidelines.pdf
6. World Health Organization. Interim Guidance Document. Clinical management of severe acute respiratory infections when novel coronavirus is suspected: What to do and what not to do. Download the PDF from:
http://www.who.int/csr/disease/coronavirus_infections/InterimGuidance_ClinicalManagement_NovelCoronavirus_11Feb13u.pdf
7. Hayden FG. Advances in antivirals for non-influenza respiratory virus infections. *Influenza Other Respi Viruses* 2013;7(Suppl. 3): 36–43. Download the PDF from:
<http://onlinelibrary.wiley.com/doi/10.1111/irv.12173/pdf>
8. Cheng VCC, Chan JFW, To KKKW, Yuen KY. Clinical management and infection control of SARS: lessons learned. *Antivir Res* 2013;100:407-419. Download the PDF from:
<http://www.sciencedirect.com/science/article/pii/S0166354213002246>
9. Momattin H, Mohammed K, Zumla A, Memish ZA, Al-Tawfiq JA. Therapeutic Options for MERS-CoV – possible lessons from a systematic review of SARS-CoV therapy. *Int J Infect Dis* 2013;17:e792–e798. Download the PDF from: [http://www.ijdonline.com/article/S1201-9712\(13\)00229-4/pdf](http://www.ijdonline.com/article/S1201-9712(13)00229-4/pdf)

Indomethacin

1. Amici C, Di Caro A, Ciucci A, et al. Indomethacin has a potent antiviral activity against SARS coronavirus. *Antiviral Ther* 2006;11(8):1021-30. Download the PDF from:
<http://www.intmedpress.com/servefile.cfm?suid=35d8dc5e-70f4-491f-acad-e35f99be9211>

Interferon

1. Loutfy MR, Blatt LM, Siminovitch KA, et al. Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study. *JAMA* 2003;290(24):3222-8 Download the PDF from:
<http://jama.jamanetwork.com/data/Journals/JAMA/4909/JPC30087.pdf>
2. Haagmans BL, Kuiken T, Martina BE, et al. Pegylated interferon- α protects type 1 pneumocytes against SARS coronavirus infection in macaques. *Nat Med* 2004;10(3):290-93 Download the PDF from:
<http://www.nature.com/nm/journal/v10/n3/pdf/nm1001.pdf>
3. Sainz B, Jr., Mossel EC, Peters CJ, Garry RF. Interferon-beta and interferon-gamma synergistically inhibit the replication of severe acute respiratory syndrome-associated coronavirus (SARS-CoV). *Virology* 2004;329(1):11-7. Download the PDF from:
http://pdn.sciencedirect.com/science?_ob=MiamilImageURL&_cid=272412&_user=126524&_pii=S0042682204005422&_check=y&_origin=article&_zone=toolbar&_coverDate=2004--10&view=c&originContentFamily=serial&wchp=dGLzVlt-zSkzV&md5=4dd23a54bf727d8ddbcebfbad784b9f61&pid=1-s2.0-S0042682204005422-main.pdf
4. Scagnolari C, Vicenzi E, Bellomi F, et al. Increased sensitivity of SARS-coronavirus to a combination of human type I and type II interferons. *Antivir Ther* 2004;9(6):1003-11. Download the PDF from:
<http://www.intmedpress.com/serveFile.cfm?sUID=175607d8-e6a4-439e-a9d2-e345e2ec3ef4>

5. Wong CK, Lam CW, Wu AK, et al. Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. *Clin Exp Immunol* 2004;136(1):95-103. Download the PDF from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1808997/pdf/cei0136-0095.pdf>
6. Barnard DL, Day CW, Bailey K, et al. Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice. *Antivir Chem Chemother* 2006;17(5):275-84. Download the PDF from: <http://www.intmedpress.com/serveFile.cfm?sUID=9ed38ddd-648c-40ad-9a4c-3e4a9a42f562>
7. Haagmans BL, Osterhaus ADME. Coronaviruses and their therapy. *Antivir Res* 2006;71(2-3 Spec Iss):397-403. Download the PDF from: http://pdn.sciencedirect.com/science?_ob=MiamilImageURL&_cid=271065&_user=126524&_pii=S0166354206001707&_check=y&_origin=article&_zone=toolbar&_coverDate=30-Sep-2006&view=c&originContentFamily=serial&wchp=dGLbVIV-zSkzk&md5=26b1488e1ded8003a395f5f40e450b8b&pid=1-s2.0-S0166354206001707-main.pdf
8. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. *PLoS Med* 2006;3(9):e343. Download the PDF from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1564166/pdf/pmed.0030343.pdf>
9. Cervantes-Barragan L, Züst R, Weber F, et al. Control of coronavirus infection through plasmacytoid dendritic-cell- derived type I interferon. *Blood* 2007;109(3):1131-37. Download the PDF from: <http://bloodjournal.hematologylibrary.org/content/109/3/1131.full.pdf>
10. Wong SSY, Yuen KY. The management of coronavirus infections with particular reference to SARS. *J Antimicrob Chemoth* 2008;62(3):437-41. Download the PDF from: <http://jac.oxfordjournals.org/content/62/3/437.full.pdf+html>
11. Danesh A, Cameron CM, Leon AJ, et al. Early gene expression events in ferrets in response to SARS coronavirus infection versus direct interferon-alpha2b stimulation. *Virology* 2011;409(1):102-Download the PDF from: http://pdn.sciencedirect.com/science?_ob=MiamilImageURL&_cid=272412&_user=126524&_pii=S0042682210006380&_check=y&_origin=article&_zone=toolbar&_coverDate=2011--05&view=c&originContentFamily=serial&wchp=dGLbVBA-zSkWz&md5=7be2dc3e06c7b3a12b2b68f6df70421c&pid=1-s2.0-S0042682210006380-main.pdf
12. Bruno R, Sacchi P, Cima S, et al. Comparison of peginterferon pharmacokinetic and pharmacodynamic profiles. *J Viral Hepatitis* 2012;19 Suppl 1:33-6. Download the PDF from: <http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2893.2011.01519.x/pdf>
13. Cameron MJ, Kelvin AA, Leon AJ, et al. Lack of Innate Interferon Responses during SARS Coronavirus Infection in a Vaccination and Reinfection Ferret Model. *PloS One* 2012;7(9). Download the PDF from: <http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0045842>
14. Mordstein M, Neugebauer E, Ditt V, et al. Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. *J Virol* 2010;84(11):5670-7. Download the PDF from: <http://jvi.asm.org/content/84/11/5670.full>

15. Kindler E, Jónsdóttir HR, Muth D, et al. Efficient Replication of the Novel Human Betacoronavirus EMC on Primary Human Epithelium Highlights Its Zoonotic Potential. *mBio* 4(1): doi:10.1128/mBio.00611-12. Download the PDF from: <http://mbio.asm.org/content/4/1/e00611-12.full.html>

16. Falzarano D, de Wit E, Martellaro C, Callison J, Munster VJ, Feldmann H. Inhibition of novel human coronavirus-EMC replication by a combination of interferon- α 2b and ribavirin. *Sci Rep* 2013 - 3,1686;DOI:10.1038/srep01686. Download the PDF from: <http://www.biomedsearch.com/attachments/00/23/59/49/23594967/srep01686.pdf>

17. de Wilde AH, Ray VS, Oudshoorn D, et al. Human coronavirus-EMC replication induces severe in vitro cytopathology and is strongly inhibited by cyclosporin A or interferon- α treatment. *J Gen Virol*. 2013 Apr 25. [Epub ahead of print]. Download the PDF from: <http://vir.sgmjournals.org/content/early/2013/04/24/vir.0.052910-0.long>

18. Morgenstern B, Michaelis M, Baer PC, Doerr HW, Cinatl J Jr. Ribavirin and interferon- β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. *Biochem Biophys Res Commun*. 2005 Jan 28;326(4):905-8. Download the PDF from: <http://www.sciencedirect.com/science/article/pii/S0006291X04027299>

19. Chan JF, Chan KH, Kao RY, et al. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. *J Infect* 2013;67(6):606-16. Download the PDF from: [http://www.journalofinfection.com/article/S0163-4453\(13\)00298-3/pdf](http://www.journalofinfection.com/article/S0163-4453(13)00298-3/pdf)

20. Adedeji AO, Sarafianos SG. Future treatment strategies for novel Middle East respiratory syndrome coronavirus infection. *Future Med Chem* 2013;5(18):2119–2122. Download the PDF from: http://www.researchgate.net/publication/258827095_Future_treatment_strategies_for_novel_Middle_East_respiratory_syndrome_coronavirus_infection

21. Al-Tawfiq JA, Momattin H, Dib J, Memish ZA. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. *Int J Infect Dis* (2014), <http://dx.doi.org/10.1016/j.ijid.2013.12.003>

22. Hart BJ, Dyall J, Postnikova E, Zhou H, Kindrachuk J, Johnson RF, Olinger GG, Frieman MB, Holbrook MR, Jahrling PB, Hensley L. Interferon- β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell based assays. *J Gen Virol* 2014;95:571-577. Download the PDF from: http://vir.sgmjournals.org/content/95/Pt_3/571.full.pdf+html?sid=b01f8c80-bde3-49d9-b716-c9b153f5dddc

Intravenous immunoglobulin

1. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. *PLoS Med* 2006;3(9):e343. Download the PDF from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1564166/pdf/pmed.0030343.pdf>

2. Katz U, Achiron A, Sherer Y, et al. Safety of intravenous immunoglobulin (IVIG) therapy. *Autoimmun Rev* 2007;6(4):257-9. Download the PDF from: <http://www.sciencedirect.com/science/article/pii/S1568997206001352>

Mannose-binding lectin

1. Ip WK, Chan KH, Law HK, et al. Mannose-binding lectin in severe acute respiratory syndrome coronavirus infection. *J Infect Dis* 2005;191(10):1697-704. Download the PDF from: <http://jid.oxfordjournals.org/content/191/10/1697.full.pdf+html>
2. Zhou Y, Lu K, Pfefferle S, et al. A single asparagine-linked glycosylation site of the severe acute respiratory syndrome coronavirus spike glycoprotein facilitates inhibition by mannose-binding lectin through multiple mechanisms. *J Virol* 2010;84(17):8753-64. Download the PDF from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2919028/pdf/0554-10.pdf>
3. Michelow IC, Lear C, Scully C, et al. High-dose mannose-binding lectin therapy for Ebola virus infection. *J Infect Dis* 2011;203(2):175-9. Download the PDF from: <http://jid.oxfordjournals.org/content/203/2/175.full.pdf+html>

Methylprednisolone

1. Soo YO, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. *Clinical Microbiol Infect* 2004;10(7):676-8. Download the PDF from: <http://onlinelibrary.wiley.com/doi/10.1111/j.1469-0691.2004.00956.x/pdf>
2. Sung JJ, Wu A, Joynt GM, et al. Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. *Thorax* 2004;59(5):414-20. Download the PDF from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1746995/pdf/v059p00414.pdf>

Mycophenolic acid

1. Chan JF, Chan KH, Kao RY, To KK, Zheng BJ, Li CP, Li PT, Dai J, Mok FK, Chen H, Hayden FG, Yuen KY. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. *J Infect* 2013;67(6):606-16. Download the PDF from: [http://www.journalofinfection.com/article/S0163-4453\(13\)00298-3/pdf](http://www.journalofinfection.com/article/S0163-4453(13)00298-3/pdf)
2. Hart BJ, Dyal J, Postnikova E, Zhou H, Kindrachuk J, Johnson RF, Olinger GG, Frieman MB, Holbrook MR, Jahrling PB, Hensley L. Interferon- β and mycophenolic acid are potent inhibitors of Middle East respiratory syndrome coronavirus in cell based assays. *J Gen Virol* 2014;95:571-577. Download the PDF from: http://vir.sgmjournals.org/content/95/Pt_3/571.full.pdf

Nitazoxinide

1. Belardo G, La Frazia S, Cenciarelli O. Nitazoxanide, a Novel Potential Anti-Influenza Drug, Acting in Synergism with Neuraminidase Inhibitors. *IDSA 2011*; abstract 1181. Download the PDF from: <https://idsa.confex.com/idsa/2011/webprogram/Paper31075.html>
2. Haffi Zulla J, Hartman A, Hoppers M et al. Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza – a double blind, randomised, placebo-controlled phase 2b/3 trial. *Rossignol JF, Samudrala S, Hoppers M. Lancet infect Dis* 2014. Download the PDF from <http://www.sciencedirect.com/science/article/pii/S1473309914707170>

Polyclonal antibodies

1. Zhang MY, Choudhry V, Xiao X, Dimitrov DS. Human monoclonal antibodies to the S glycoprotein and related proteins as potential therapeutics for SARS. *Curr Opin Mol Ther* 2005;7(2):151-56. Abstract only: <http://www.ncbi.nlm.nih.gov/pubmed/15844623>

Protease inhibitors

1. Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. *Thorax* 2004;59(3):252-6. Download the PDF from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1746980/pdf/v059p00252.pdf>

2. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. *PLoS Med* 2006;3(9):e343. Download the PDF from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1564166/pdf/pmed.0030343.pdf>

3. Wong SSY, Yuen KY. The management of coronavirus infections with particular reference to SARS. *J Antimicrob Chemoth* 2008;62(3):437-41. Download the PDF from: <http://jac.oxfordjournals.org/content/62/3/437.full.pdf+html>

4. Barnard DL, Kumaki Y. Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy. *Future Virol* 2011;6(5):615-31. Download the PDF from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3136164/pdf/nihms304163.pdf>

5. Chan KS, Lai ST, Chu CM, et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicenter retrospective matched cohort study. *Hong Kong Med J* 2003;9: 399–406. Download the PDF from: http://www.hkmj.org/article_pdfs/hkm0312p399.pdf

6. de Wilde AH, Jochmans D, Posthuma CC et al. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. *Antimicrob Agents Chemother*. 2014 May 19. Download the PDF from: <http://aac.asm.org/content/early/2014/05/13/AAC.03011-14.full.pdf+html>

Ribavirin

1. van Vonderen MGA, Bos JC, Prins JM, Wertheim-van Dillen P, Speelman P. Ribavirin in the treatment of severe acute respiratory syndrome (SARS). *Neth J Med* 2003;61(7):238-41. Download the PDF from: <http://www.njmonline.nl/getpdf.php?t=a&id=62>

2. Lee N, Allen Chan KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. *J Clin Virol* 2004;31(4):304-9. Download the PDF from: <http://www.sciencedirect.com/science/article/pii/S1386653204001957>

3. Soo YO, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. *Clin Microbiol Infect* 2004;10(7):676-8. Download the PDF from: <http://onlinelibrary.wiley.com/doi/10.1111/j.1469-0691.2004.00956.x/pdf>

4. Sung JJ, Wu A, Joynt GM, et al. Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. *Thorax* 2004;59(5):414-20. Download the PDF from: <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1746995/pdf/v059p00414.pdf>

5. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. *PLoS Med* 2006;3(9):e343. Download the PDF from:
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1564166/pdf/pmed.0030343.pdf>
6. Falzarano D, de Wit E, Martellaro C, Callison J, Munster VJ, Feldmann H. Inhibition of novel human coronavirus-EMC replication by a combination of interferon- α 2b and ribavirin. *Sci Rep* 2013 - 3, 1686; DOI:10.1038/srep01686. Download the PDF from:
<http://www.biomedsearch.com/attachments/00/23/59/49/23594967/srep01686.pdf>
7. Morgenstern B, Michaelis M, Baer PC, Doerr HW, Cinatl J Jr. Ribavirin and interferon-beta synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines. *Biochem Biophys Res Commun* 2005;326(4):905-8. Download the PDF from:
<http://www.sciencedirect.com/science/article/pii/S0006291X04027299>
8. Chan JF, Chan KH, Kao RY, To KK, Zheng BJ, Li CP, Li PT, Dai J, Mok FK, Chen H, Hayden FG, Yuen KY. Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. *J Infect* 2013;67(6):606-16. Download the PDF from: [http://www.journalofinfection.com/article/S0163-4453\(13\)00298-3/pdf](http://www.journalofinfection.com/article/S0163-4453(13)00298-3/pdf)
9. Adedeji AO, Sarafianos SG. Future treatment strategies for novel Middle East respiratory syndrome coronavirus infection. *Future Med Chem* 2013;5(18):2119–2122. Download the PDF from:
http://www.researchgate.net/publication/258827095_Future_treatment_strategies_for_novel_Middle_East_respiratory_syndrome_coronavirus_infection
10. Al-Tawfiq JA, Mommatin H, Dib J, Memish ZA. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. *Int J Infect Dis* (2014), <http://dx.doi.org/10.1016/j.ijid.2013.12.003>

SiRNA

1. Li BJ, Tang Q, Cheng D, et al. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque. *Nat Med* 2005;11(9):944-51. Download the PDF from:
<http://www.nature.com/nm/journal/v11/n9/pdf/nm1280.pdf>
2. Haagmans BL, Osterhaus ADME. Coronaviruses and their therapy. *Antivir Res* 2006;71(2-3 Spec. Iss.):397-403. Download the PDF from:
http://pdn.sciencedirect.com/science?_ob=MiamiImageURL&_cid=271065&_user=126524&_pii=S0166354206001707&_check=y&_origin=article&_zone=toolbar&_coverDate=30-Sep-2006&view=c&originContentFamily=serial&wchp=dGLbVIV-zSkzk&md5=26b1488e1ded8003a395f5f40e450b8b&pid=1-s2.0-S0166354206001707-main.pdf

Viral loads

1. Hung IF, Cheng VC, Wu AK, et al. Viral loads in clinical specimens and SARS manifestations. *Emerg Infect Dis* 2004;10(9):1550-7. Download the PDF from:
<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3320271/pdf/04-0058.pdf>